Physicians' Opinion and Practice With the Continuous Use of Sedatives in the Last Days of Life.

Continuous use of sedatives Deep sedation End of life care Palliative care Palliative sedation Questionnaire study

Journal

Journal of pain and symptom management
ISSN: 1873-6513
Titre abrégé: J Pain Symptom Manage
Pays: United States
ID NLM: 8605836

Informations de publication

Date de publication:
01 2022
Historique:
received: 08 03 2021
revised: 20 07 2021
accepted: 21 07 2021
pubmed: 2 8 2021
medline: 1 3 2022
entrez: 1 8 2021
Statut: ppublish

Résumé

There are few international studies about the continuous use of sedatives (CUS) in the last days of life. We aim to describe the experiences and opinions regarding CUS of physicians caring for terminally ill patients in seven countries. Questionnaire study about practices and experiences with CUS in the last days of life among physicians caring for terminally ill patients in Belgium (n = 175), Germany (n = 546), Italy (n = 214), Japan (n = 513), the Netherlands (n = 829), United Kingdom (n = 114) and Singapore (n = 21). The overall response rate was 22%. Of the respondents, 88-99% reported that they had clinical experience of CUS in the last 12 months. More than 90% of respondents indicated that they mostly used midazolam for sedation. The use of sedatives to relieve suffering in the last days of life was considered acceptable in cases of physical suffering (87%-99%). This percentage was lower but still substantial in cases of psycho-existential suffering in the absence of physical symptoms (45%-88%). These percentages were lower when the prognosis was at least several weeks (22%-66% for physical suffering and 5%-42% for psycho-existential suffering). Of the respondents, 10% or less agreed with the statement that CUS is unnecessary because suffering can be alleviated with other measures. A substantial proportion (41%-95%) agreed with the statement that a competent patient with severe suffering has the right to demand the use of sedatives in the last days of life. Many respondents in our study considered CUS acceptable for the relief of physical and psycho-existential suffering in the last days of life. The acceptability was lower regarding CUS for psycho-existential suffering and regarding CUS for patients with a longer life expectancy.

Identifiants

pubmed: 34333097
pii: S0885-3924(21)00469-3
doi: 10.1016/j.jpainsymman.2021.07.012
pii:
doi:

Substances chimiques

Hypnotics and Sedatives 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

78-87

Subventions

Organisme : Marie Curie
ID : MCCC-FCH-18-U
Pays : United Kingdom
Organisme : Marie Curie
ID : MCCC-FCO-11-U
Pays : United Kingdom
Organisme : Marie Curie
ID : MCCC-FPO-16-U
Pays : United Kingdom

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Madelon T Heijltjes (MT)

Department of Medical Humanities, Julius Center for Health Sciences and Primary Care (M.T.H., J.J.M.V.D.), UMC Utrecht, Utrecht, The Netherlands. Electronic address: m.t.heijltjes-2@umcutrecht.nl.

Tatsuya Morita (T)

Palliative and Supportive Care Division (T.M., M.M.), Seirei Mikatahara General Hospital, Shizuoka, Japan.

Masanori Mori (M)

Palliative and Supportive Care Division (T.M., M.M.), Seirei Mikatahara General Hospital, Shizuoka, Japan.

Maria Heckel (M)

Department of Palliative Medicine (M.H., C.K.), CCC Erlangen - EMN, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Carsten Klein (C)

Department of Palliative Medicine (M.H., C.K.), CCC Erlangen - EMN, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Stephanie Stiel (S)

Hannover Medical School (S.S.), Institute for General Practice and Palliative Care, Düsseldorf, Germany.

Guido Miccinesi (G)

Oncological network (G.M.), Prevention and Research Institute-ISPRO, Firenze, Italy.

Luc Deliens (L)

Vrije Universiteit Brussel (L.D.), Ixelles, Belgium.

Lenzo Robijn (L)

Department of Public Health and Primary Care (L.R.), Ghent University, Ghent, Belgium.

Patrick Stone (P)

Marie Curie Palliative Care Research Department (P.S., N.S.), University College London, London, United Kingdom.

Nigel Sykes (N)

Marie Curie Palliative Care Research Department (P.S., N.S.), University College London, London, United Kingdom.

David Hui (D)

MD Anderson Cancer Center (D.H.), University of Texas, Texas, USA.

Lalit Krishna (L)

National Cancer Center Singapore (L.K.), Singapore.

Johannes J M van Delden (JJM)

Department of Medical Humanities, Julius Center for Health Sciences and Primary Care (M.T.H., J.J.M.V.D.), UMC Utrecht, Utrecht, The Netherlands.

Agnes van der Heide (A)

Erasmus MC (A.V.D.H., J.A.C.R.), University Medical Center Rotterdam, Rotterdam, The Netherlands.

Judith A C Rietjens (JAC)

Erasmus MC (A.V.D.H., J.A.C.R.), University Medical Center Rotterdam, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH